Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://www.springerlink.com/index/pdf/10.1532/IJH97.04050
Reference74 articles.
1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House,Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
4. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717-720.
5. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mitoxantrone stacking does not define the active or inactive state of USP15 catalytic domain;Journal of Structural Biology;2022-09
2. Marginal zone lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up;Saudi Journal of Medicine and Medical Sciences;2019
3. Mechanisms of Resistance to Anticancer Agents;Frontiers in Antimicrobial Resistance;2014-04-30
4. Older and New Formulations of Cladribine: Pharmacology and Clinical Efficacy in Hematological Malignancies;Frontiers in Anti-Cancer Drug Discovery;2011-03-26
5. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma;European Journal of Haematology;2010-12-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3